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Purpose: We evaluated the performance of the recently extended
Breast and Ovarian Analysis of Disease Incidence and Carrier
Estimation Algorithm (BOADICEA version 5) in a Dutch
prospective cohort, using a polygenic risk score (PRS) based on
313 breast cancer (BC)–associated variants (PRS313) and other,
nongenetic risk factors.
Methods: Since 1989, 6522 women without BC aged 45 or older of
European descent have been included in the Rotterdam Study. The
PRS313 was calculated per 1 SD in controls from the Breast Cancer
Association Consortium (BCAC). Cox regression analysis was
performed to estimate the association between the PRS313 and
incident BC risk. Cumulative 10-year risks were calculated with
BOADICEA including different sets of variables (age, risk factors
and PRS313). C-statistics were used to evaluate discriminative
ability.
Results: In total, 320 women developed BC. The PRS313 was
significantly associated with BC (hazard ratio [HR] per SD of 1.56,
95% confidence interval [CI] [1.40–1.73]). Using 10-year risk
estimates including age and the PRS313, other risk factors improved
the discriminatory ability of the BOADICEA model marginally,
from a C-statistic of 0.636 to 0.653.
Conclusions: The effect size of the PRS313 is highly reproducible in
the Dutch population. Our results validate the BOADICEA v5
model for BC risk assessment in the Dutch general population.
Genetics in Medicine (2020) https://doi.org/10.1038/s41436-020-
0884-4
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INTRODUCTION
Breast cancer is the most common cancer among women in
Europe.1 In the Netherlands, the average lifetime risk for
developing invasive breast cancer is 13.6% for each woman,
with the incidence peaking between 60 and 70 years of age.2
Mammographic screening has decreased breast cancer
mortality at the cost of detecting more disease that otherwise
would not have become clinically apparent.3,4 Based on the
UK guidelines, for every 10,000 women invited for screening
at age 50 for the following 20 years, 43 deaths would be
prevented, while 129 breast cancers would be overdiagnosed.5
Furthermore, breast cancer screening inevitably yields false
positives, which can lead to anxiety.6 Improvement of this
benefit-to-harm ratio could be achieved by targeting women
who benefit the most from screening, in particular those in
the highest risk categories, while reducing screening for those
in the lowest risk categories, potentially reducing
overdiagnosis and costs while maintaining a reduced breast
cancer death rate and improved quality of life.7
Many risk prediction algorithms have been developed to
quantify the combined effect of various risk factors to predict
the risk of developing breast cancer.8,9 The recently extended
Breast and Ovarian analysis of Disease Incidence and Carrier
Estimation Algorithm (BOADICEA) calculates cumulative
risk of developing breast cancer based on family history,
mammographic density, and several lifestyle/hormonal and
genetic risk factors.10 BOADICEA includes the rare high to
moderate risk pathogenic variants in breast cancer genes
BRCA1, BRCA2, PALB2, CHEK2, and ATM, and a polygenic
risk score (PRS) based on 313 breast cancer–associated
variants (PRS313). In ten prospective studies, this PRS showed
an association with breast cancer with an odds ratio (OR) of
1.61 per standard deviation (SD) of the PRS distribution,11
and an area under receiver–operator curve of 0.630. It has
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been shown that the greatest breast cancer risk stratification
in the general population and in women with a family history
of breast cancer can be obtained by using the combined effects
of the PRS and lifestyle/hormonal risk factors in the
BOADICEA model.10
Currently, breast cancer screening in the Dutch popula-
tion is age-based.12 Women start at age 50 years with
biannual mammograms until the age of 75. Before
considering risk-stratified approaches based on BOADI-
CEA, it is important to assess its clinical validity in the
Dutch population. In this study we validated the association
between the PRS313 and breast cancer in a Dutch
prospective cohort, its effect on predicting in situ breast
cancer, and explore the discriminative ability of an
individualized 10-year breast cancer risk score based on
the PRS313 and several known risk factors using the
BOADICEA version 5 model. We also assessed how a
risk-based approach of population-based screening could




The Rotterdam Study (RS) is a prospective population-based
cohort study of elderly Dutch individuals living in the
Ommoord district of Rotterdam in the Netherlands.13 Briefly,
in the year 1989, individuals aged 55 or older were recruited
into the RS-I cohort, which was extended in 2000 under
similar criteria (RS-II cohort) and in 2006 by the inclusion of
individuals with an age between 45 and 55 (RS-III cohort).
The overall response rate was 72%. In 2008 the Rotterdam
Study comprised 14,926 subjects aged 45 years or older,
including 8823 women. For our study, we included all 6670
women for whom genotype data were available. Genotyping
was not performed for the excluded 2153 women because of a
low-quality DNA sample or because they declined blood
donation for DNA at study entry.
Ethics statement
The Rotterdam Study has been approved by the Medical
Ethics Committee of the Erasmus Medical Center and by the
Dutch Ministry of Health, Welfare, and Sports. All partici-
pants provided written informed consent to participate in the
study and to have their medical information obtained from
treating physicians.
Phenotype data
Diagnoses of cancer were collected for all individuals up to
January 2014 and were based on medical records of general
practitioners (including hospital discharge letters) and
through linkage with Dutch Hospital Data, Netherlands
Comprehensive Cancer Organisation, and histology and
cytopathology registries in the region.13 In total, 468 women
had a breast cancer (invasive or in situ) diagnosis of whom
148 had been diagnosed prior to entry into the Rotterdam
Study, and were excluded from further analyses. All
participants were interviewed at home at inclusion, under-
went extensive examinations every ~5 years in the
Rotterdam Study research facility, and received follow-up
questionnaires (Fig. S1), as described elsewhere.13 Basic
characteristics such as date of birth, vital status, and age at
inclusion were known for all participants. For most
participants, information on breast cancer risk factors was
available (Table S1, total cohort), but family history of
breast cancer and mammographic density were lacking.
For the analyses, we used only information from the
first questionnaire (Fig. S1: RS-I-1, RS-II-1, RS-III-1) at
the time of inclusion in the Rotterdam Study for variables
that could vary over time, e.g. weight and alcohol use.
Age at menopause was only included if menopause occurred
before enrollment into the Rotterdam Study (Table S1,
subcohort).
Genotype data
Genotyping was performed with the Illumina 550 K (RS-I and
RS-II cohorts) and 610 K (RS-III cohort) arrays.13 Standard
quality control was completed, including selection on
European ancestry, and imputation was performed using
the Haplotype Reference Consortium (HRC) 1.1 and 1000 G
phase 3 reference panels.14,15 Of the 313 variants used to
calculate the PRS, 28 were directly genotyped by the arrays.
Two variants were imputed with a quality below 0.3 and the
remaining 283 variants were imputed with an average
imputation quality of 0.95 (Table S2).
Polygenic risk score calculation





nij ln ORið Þ
where nij is the number of risk alleles (0, 1, or 2) for variant i
carried by individual j and ORi is the per-allele OR for breast
cancer associated with variant i. The ORs were obtained from
the Breast Cancer Association Consortium (BCAC) study11
(Table S2). As the estrogen receptor (ER) status of the breast
tumors was not available, only the overall breast cancer PRS
was calculated. The PRS313 was standardized to the mean in
all included women from the Rotterdam Study who did not
develop incident breast cancer. To allow for direct compar-
ison of PRS performance between both studies, the SD of the
population controls included in the validation set from the
BCAC study11 was used, which was 0.609. For the calculations
with BOADICEA version 5, the PRS313 was standardized to
the mean and SD from the population controls included in
the total data set from the BCAC study,11 which were −0.424
and 0.603 respectively.
Cumulative risk score calculation
Cumulative 10-year breast cancer risks were calculated with
BOADICEA version 5,10 starting at the age of inclusion in the
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Rotterdam Study, and using the birth cohort incidence rates
in combination with four different sets of variables, i.e., (1)
age, (2) age and PRS313, (3) age and risk factors, and (4) age,
PRS313, and risk factors. Risk factors included are age at
menarche, age at menopause, number of children, age at first
live birth, use of oral contraception, use of hormone
replacement therapy, body mass index (BMI), height, and
alcohol use. For the variables that could vary over time, we
used fixed variables. As BOADICEA ignores any risk factors
for which the value is missing,10 no imputation was
performed, and missing variables were kept missing.
Because BOADICEA calculates cumulative breast cancer
risks up to age 80, 10-year breast cancer risks were only
calculated for 4377 women with an age of inclusion up to
70 years. Women were considered affected if they developed
breast cancer (invasive or in situ) within 10 years after
inclusion in the Rotterdam Study.
Statistical analyses
Cumulative incidences were calculated using the
Kaplan–Meier method.
Association analyses
To estimate the association between the PRS313 and breast
cancer risk in the Rotterdam Study cohort, Cox regression
analyses were performed. Relatedness among individuals of
the same family was accounted for by correcting standard
errors using a sandwich estimator. All models were adjusted
by the age at inclusion in the Rotterdam Study. Incident
breast cancer, in situ or invasive, was the event of interest. The
time at risk was defined as the time elapsed between the
inclusion date and the date of occurrence of the event of
interest or right censoring. Right censoring could be due to
(1) end of follow-up in January 2014 or (2) death. The
proportional hazard assumption for the model was tested.
Sensitivity analyses were performed (1) for invasive breast
cancer only by censoring the in situ breast cancer cases, (2) for
in situ breast cancer only by censoring the invasive breast
cancer cases, (3) by censoring at the age of diagnosis of
another type of cancer, and (4) by stratifying on Rotterdam
Study cohort. To define the association between the PRS313
and other tumors than breast cancer, similar Cox regression
analysis was performed by censoring the breast cancer cases if
they did not develop another tumor before the breast cancer
diagnosis.
To investigate if the linearity assumption for the effect of
PRS313 holds, we ran the model considering the categorical
covariate given by the percentile groups of the PRS313 (0–10%,
10–20%, 20–40%, reference 40–60%, 60–80%, 80–90%,
90–100%) based on the distribution in the unaffected women
in this cohort. The discrimination ability of the PRS313 in our
sample was evaluated using the C-statistic,16 by groups based
on quantiles of the age of inclusion in the Rotterdam Study
(i.e. age <60, 60–70, and ≥70 years). Differences in the C-
statistics were tested by computing bootstrap CIs for the
differences among groups.
Age-varying effect
The possible time-varying association of the PRS313 with
breast cancer was investigated using age as time scale and
considering three age-dependent coefficients in the Cox
model, corresponding to three different age intervals:
(1) younger than 50 years, (2) between 50 and 75 years old,
and (3) above 75 years old. These cut-offs were chosen based
on their clinical relevance since women between 50 and 75
years are eligible for population screening according to the
Dutch guideline.12
Clinical validity of BOADICEA v5
To validate the BOADICEA 10-year cumulative risk scores,
model calibration and discrimination ability in our sample
were assessed. Calibration was investigated by comparing
overall observed versus expected cumulative risks and by
visually inspecting the calibration plots based on risk deciles.
Because of the presence of right censoring, empirical risks at
10 years were estimated using the Kaplan–Meier method. As
in the association analyses, discrimination was evaluated
using C-statistics.
Statistical significance was defined as a two-sided p value of
<0.05. All analyses were performed with R version 3.5.3.17
RESULTS
We included 6522 women in the main analyses with an
average age at study entry of 66 years. Of these, 320 developed
either invasive or in situ breast cancer during follow-up and
744 developed another type of tumor; the overlap between
these two groups was 16, all of whom developed another type
of tumor first (Table S3). The median follow-up calculated
with the reverse Kaplan–Meier method was 12.40 years, with
a minimum and maximum follow-up of 0.03 and 24.43 years.
Cohort characteristics are shown in Table S1. The average
PRS313 in groups of affected (i.e. invasive, in situ, and a second
breast tumor) and unaffected women (including women who
developed another tumor than breast cancer) are shown in
Fig. S2 and Table S4.
Breast cancer cumulative incidence
The cumulative incidence of breast cancer in the total cohort
was on average 4.2%, 95% CI [3.7%–4.8%] and 7.3%, 95% CI
[6.4%–8.2%] 10 and 20 years after inclusion respectively.
Stratified by quintiles of the PRS313, after 20 years of follow-
up, the incidence in the highest quintile was 10.8%, 95% CI
[8.5%–13.1%] and 4.4%, 95% CI [2.8%–6.0%] for the lowest
quintile (Fig. S3).
Association analyses
A significant association was found between the PRS313 and
incident breast cancer with an HR per SD of 1.56, 95% CI
[1.40–1.74], p= 2.47 × 10−15 (Table 1). There was no
evidence of violation of the proportional hazard assumption
(p value= 0.716), indicating that the HR remained constant
over time. The discriminative ability of the PRS313, as
measured by the C-statistic, was 0.632, 95% CI [0.58–0.69],
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0.673, 95% CI [0.61–0.73], and 0.562, 95% CI [0.48–0.62] for
women included before age 60, between age 60 and 70, and
above age 70 respectively (Table 1).
Sensitivity analyses for (1) invasive breast cancer only, (2)
censoring at another tumor if applicable, or (3) stratifying by
the Rotterdam Study subcohort all showed similar results
(Table 1). Notably, in situ breast cancer also showed a
statistically significant association with the PRS313, HR per
SD= 1.43, 95% CI [1.01–2.01], p= 0.042.
Association analyses for breast cancer and percentiles of the
PRS313 showed that the HR estimates were in line with the HR
predicted when a continuous PRS313 is assumed, under a log-
linear model (Fig. 1, Table 1).
During follow-up, 744 women developed a tumor other
than breast cancer without evidence for association with the
PRS313 (HR per SD= 1.05, 95% CI [0.98–1.12], p value=
0.195).
Age-varying effect
Extension of the Cox model allowing for age-dependent
regression coefficients showed that the performance of the
PRS313 decreased with increasing inclusion age, with the HRs
per SD declining from 2.74, 95% CI [1.72–4.37] for women
included before age 50, to 1.74, 95% CI [1.52–2.00] for women
included between 50 and 75 (pdiff= 0.066). The HR for
women included after age 75 was 1.29, 95% CI [1.08–1.55],
and the p value of the difference with respect to the youngest
group was 0.003 (Table 1).
Clinical validity of BOADICEA V5
For these analyses, we selected 4377 women with an age of
inclusion under 70 years. Of these, 163 developed breast
cancer within 10 years after inclusion (142 invasive). The
median follow-up in this subcohort was 10 years (range
0.03–10 years), and the cumulative incidence of breast cancer
was 4.4% (95% CI [3.7–5.1%]). The distributions of 10-year
cumulative risk scores under different models are shown in
Figs. S4 and S5. Irrespective of the variables included,
BOADICEA underestimated the observed risk of 4.4%
(Table 2). Accordingly, while using age and PRS313 seems to
result in the best calibration (Fig. S4C), it underestimated the
observed risks in the higher risk categories. The highest
discriminative ability was found for the model with age,
PRS313 and all available risk factors (0.653, 95% CI
[0.60–0.70]), henceforth the “full” model. The PRS313 was
the strongest factor contributing to discrimination, relative to
age and other risk factors (Table 2).
Using the full model and a threshold of 2.5% 10-year breast
cancer risk, which approximates the risk of women entering
the age-based population screening program in the
Table 1 Results of the association analyses between breast cancer and the PRS313.
n Included n Events HR 95% CI p value C-statisticc 95% CI
Main analyses 6522 320 1.56 1.40–1.74 2.47×10−15
Age category for discriminative ability of the PRS
<60 2175 104 0.632 0.58–0.69
60–70 2174 128 0.673 0.61–0.73
≥70 2173 88 0.562 0.48–0.62
Sensitivity analyses
Invasive BC only 6522 290a 1.57 1.40–1.77 1.34 × 10−14
In situ BC only 6522 34 1.43 1.01–2.01 0.042
Censored at other tumor 6402b 298 1.54 1.37–1.73 1.88 × 10−13
Stratified by RS cohort 6522 320 1.56 1.40–1.75 1.92 × 10−15
Percentage of the PRS
0–10% 637 17 0.59 0.34–1.01 0.053
10–20% 636 16 0.58 0.33–1.01 0.053
20–40% 1283 42 0.73 0.49–1.09 0.120
40–60% 1298 57 1.00 Reference Reference
60–80% 1325 85 1.49 1.07–2.09 0.019
80–90% 656 36 1.28 0.84–1.94 0.251
90–100% 687 67 2.37 1.66–3.37 1.73 × 10−06
Age category for time-varying analyses
<50 224 2 2.74 1.72–4.37 2.23 × 10−05
50–75 5104 197 1.74 1.52–2.00 2.21 × 10−15
>75 4032 121 1.29 1.08–1.55 0.005
BC breast cancer, CI confidence interval, HR hazard ratio, PRS polygenic risk score, RS Rotterdam Study.
a4 women developed an invasive breast tumor after development of an in situ breast tumor.
b120 women were excluded from analyses because they developed another tumor before inclusion in the Rotterdam Study.
cThe corresponding differences in C-statistic were for women with inclusion age 60–70 versus age <60: 0.041, 95% CI [−0.05–0.12]; for women with inclusion age
60–70 versus age ≥70: 0.111, 95% CI [0.02–0.21]; for women with inclusion age <60 versus age ≥70: 0.070, 95% CI [−0.01–0.18].
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Netherlands, 101 cases (62% of incident cases) occurred in a
screening group of 1956 women (45% of total) and 62 breast
cancers occurred in 2421 women who would not be screened
(Fig. 2; Table 3). Using the PRS313 and age only, 130 cases
(80% of incident cases) occurred in a screening group of 2863
women (65% of total); in 1481 women who would not be
screened, 33 breast cancers occurred. In Fig. S6 the
percentages of incident breast cancer cases and unaffected
women are shown for different category thresholds. For both
models, the invasive cancers in the group selected for
screening were more likely to be of lower grade compared
with the cancers in the nonscreened group (Table 3). The
reverse effect was found for in situ cancers.
DISCUSSION
Many risk factors for breast cancer, both genetic and
nongenetic, have been identified in the past decades.18,19
Increasingly, these are being integrated into computational
models that allow personalized breast cancer risk assessment,
which has potential application beyond current practice of
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Fig. 1 Association with the PRS313 and breast cancer risk. Plot of the HR for the association between the PRS313 and breast cancer risk based on PRS313
percentiles. The PRS313 percentile groups are 0–10%, 10–20%, 20–40%, 40–60% (reference), 60–80%, 80–90%, 90–100% based on the distribution in
unaffected women. The numbers and corresponding effect sizes are shown in Table 1. The solid line represents the continuous distribution based on the per
SD effect size of the PRS313. CI confidence interval, HR hazard ratio, PRS polygenic risk score.
Table 2 Range and discriminative ability of the cumulative 10-year breast cancer risk scores calculated with BOADICEA.
Variables included Mean % (range) C-statistic 95% CI
Unaffected women BC casesa
Age 3.0 (2.2–3.6) 2.9 (2.2–3.6) 0.531 0.50–0.58
Age, risk factors 2.5 (1.0–5.9) 2.6 (1.4–4.3) 0.558 0.52–0.60
Age, PRS313 3.1 (0.6–11.9) 3.8 (1.2–8.3) 0.636 0.59–0.68
Age, risk factors, PRS313 2.6 (0.4–11.4) 3.3 (0.9–10.5) 0.653 0.60–0.70
BC breast cancer, BOADICEA Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, CI confidence interval, PRS polygenic risk score.
aWomen who developed BC within 10 years of follow-up.
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0.0 2.5 5.0 7.5 10.0 0.0
Incident BC cases, N=163 Unaffected women, N=4214
2.5 5.0
BOADICEA 10-year cumulative risk %
Age and risk factors Age and PRS Age, risk factors and PRS
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Fig. 2 Cumulative 10-year breast cancer risk distribution predicted by BOADICEA. Density plots of the cumulative 10-year risk calculated by
BOADICEA for unaffected women and incident breast cancer cases. Including age and risk factors (left), including age and the PRS313 (middle), and the full
model including age, risk factors and the PRS313. The dashed line shows the threshold of a 10-year risk of 2.5%. BOADICEA Breast and Ovarian Analysis of
Disease Incidence and Carrier Estimation Algorithm, PRS polygenic risk score.
Table 3 Numbers and percentages of women per 10-year risk category.
10-year risk category based on BOADICEA
Total Including age and PRS Including age, risk factors, and PRS
<2.5% >2.5% <2.5% >2.5%
Unaffected women
All 4214 1481 (35%) 2733 (65%) 2359 (56%) 1855 (44%)
Incident BC cases
All 163 33 (20%) 130 (80%) 62 (38%) 101 (62%)
Invasive BC
All 142 30 (21%) 112 (79%) 52 (37%) 90 (63%)
Grade 1 19 2 (11%) 17 (89%) 3 (16%) 16 (84%)
Grade 2 38 7 (18%) 31 (82%) 12 (32%) 26 (68%)
Grade 3 43 13 (30%) 30 (70%) 21 (49%) 22 (51%)
Unknown 42 8 (19%) 34 (81%) 16 (38%) 26 (62%)
In situ BC
All 21 3 (14%) 18 (86%) 10 (48%) 11 (52%)
Grade 1 3 2 (67%) 1 (33%) 2 (67%) 1 (33%)
Grade 2 3 1 (33%) 2 (67%) 2 (67%) 1 (33%)
Grade 3 13 0 (0%) 13 (100%) 5 (38%) 8 (62%)
Unknown 2 0 (0%) 2 (100%) 1 (50%) 1 (50%)
BC breast cancer, BOADICEA Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm, PRS polygenic risk score.
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genetic testing in family cancer clinics.8,9,20 The BOADICEA
algorithm is among the most comprehensive risk models
presently available for breast cancer risk assessment.10 Here,
we validated the most recent version of this model in a large
prospective population-based Dutch cohort of women above
45 years, which has not been part of the previously published
BCAC study.11 Unsurprisingly, the best discrimination was
achieved after inclusion of all available risk factors, with the
largest contribution deriving from the PRS313. The PRS313 was
significantly associated with breast cancer, with a similar
effect size as in other prospective series of different geographic
origin,11 demonstrating its robustness and potential applica-
tion to the Dutch population.
The PRS313 improved the discriminatory ability from 0.531
to 0.636, compared with a model using age only, which could
only be marginally improved further (to 0.653) by adding
lifestyle, reproductive factors, and anthropometric data. This
is in line with previous research, showing that the variance
explained by the risk factors is modest compared with the
PRS313 risk stratification.
10,21 Results of the calibration
showed that BOADICEA underestimated the observed risks,
especially in the higher categories of risk. One possible
explanation is that BOADICEA v5 uses the population breast
cancer incidences of the United Kingdom as baseline risk,
which are slightly lower than those in the Netherlands.1 But
more importantly, data on family history, mammographic
density, and rare high-risk variants in BRCA1 and BRCA2
were lacking in our cohort. In another prospective validation
study of a previous version of BOADICEA in two cohorts of
women from Australia, Canada, and the United States,
information on family history and BRCA1/2 carrier status,
but not the PRS313, was available, and here, BOADICEA
overestimated 10-year cumulative risks in the highest risk
quantile.9 Possibly, the missing data on family history and
BRCA1/2 status in the Rotterdam Study were in fact more
prevalent than modeled by BOADICEA. Our calibration
results indicate that for proper use in the general population,
information on family history may be important.
We illustrated the potential impact of the model in
detecting breast cancer in a population screening setting in
which women would participate based on their individual
risk. In this illustration, the PRS313 alone would have detected
more cases than the full BOADICEA model, but would also
have identified a larger screening group. Apparently, women
in the Rotterdam Study have on average fewer nongenetic risk
factors compared with the total population, which on average
slightly modifies their risk in a downward direction. The
PROCAS study used the Tyrer–Cuzick model with mammo-
graphic density and risk factors, combined with a PRS based
on 18 single-nucleotide polymorphisms (SNPs);22 they found
82% of the cases to occur in 68% of women with a 10-year
breast cancer risk above 2%, i.e., very similar to what we
found with the PRS313 alone.
Remarkably, we found the proportion of low grade invasive
tumors to be higher in those with a 10-year risk >2.5%,
compared with those with lower risks. Screen-detected
invasive cancers are more likely of lower grade and stage.23
Our cohort data did not include information on whether
incident breast cancers were screen-detected or not, hence we
cannot exclude that high-risk women disproportionally self-
selected for mammographic screening, which could explain
this bias. In contrast, for the in situ carcinomas, more high
grade tumors were found in the >2.5% 10-year risk group
compared with those with lower risks. Histological grade of
ductal carcinoma in situ (DCIS) has been suggested to be one
of six factors associated with subsequent development of
invasive disease,24 albeit not very strongly so. It remains
possible that the PRS313 is more strongly associated with low
grade invasive breast cancer than with higher grades, as
observed for some individual variants,25,26 and inversely so for
DCIS. It will be important to replicate this in larger studies to
inform the evaluation of the cost-effectiveness of a risk-based
versus age-based entry of the population screening.7
Although PRS development studies have included only
invasive breast cancer,11,27 in our cohort the PRS313 is
associated with in situ breast cancer as well, with a
nonsignificantly lower effect size than for invasive breast
cancer. This corresponds well with a previously reported
association of an 18-SNP-based PRS22 and with previous
results showing that the association of 51 of the 76
investigated breast cancer loci with DCIS is in the same
direction as for invasive breast cancer.28 Although BOADI-
CEA is presented as a model that predicts invasive breast
cancer,10 these results suggest it might also predict in situ
breast cancer. Larger studies are needed to confirm this and
provide more accurate risk estimates, specifically in the setting
of population screening programs.
As in previous studies,11,27 we found that the effect size of
the PRS for breast cancer declined with increasing age. While
this is not yet modeled in BOADICEA, this could be
important to consider for women under the age of 50 who
are at this moment not eligible for population breast cancer
screening in the Netherlands, because our results suggest that
using the overall HR would be underestimating risk in this
age group.
In the Rotterdam Study, malignancies other than breast
cancer are also recorded. We found no evidence for
association of the PRS313 with these cancers, suggesting it
specifically predicts breast cancer. Another prospective study
also reported no association between other types of cancer
and a sum of breast cancer risk alleles at 72 loci.29 Because we
only analyzed all other tumors combined, we cannot exclude
that the PRS313 has an association with one specific type of
other cancer.
A strength of our study is the prospective population-based
study design, including all women in a specified locale near
Rotterdam. Because of the high response rate (>70%) it is a
good representation of the Dutch population in that age
category.13 Furthermore, for a large group of women, there is
extensive follow-up of up to 25 years.
Besides that information on mammographic density and
family history was lacking, another limitation of our study is
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the unknown ER status of the breast tumors, precluding the
analysis of ER-positive and ER-negative disease separately.
Furthermore, to evaluate the introduction of risk-based entry
into population screening, establishing the detection rate of
breast cancers below the age of 50 would have been relevant,
which was not possible in our older cohort of women. Finally,
we excluded nearly 25% of all women in the Rotterdam Study
because no genotyping data were available. Declining blood
donation for DNA extraction did not lead to differences in the
basic characteristics between the genotyped and nongeno-
typed groups. Therefore, if a selection bias was present, we
believe this bias would be small.
In summary, the PRS313 replicates robustly in the Dutch
population and the discriminative power of the BOADICEA
model seems appropriate for implementation into breast
cancer prevention programs, such as those currently ongoing
in cancer family clinics in many countries worldwide.
However, application to the general population would require
recalibration of BOADICEA to address underestimation in
the higher risk categories. Although the Rotterdam Study
design precluded analysis of breast cancer–specific mortality,
our evaluation of clinical validity provides first insights into
how a risk-based entry could impact the efficacy of the breast
cancer population screening program in the Netherlands.
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